Chimerix, Inc. (NASDAQ:CMRX) Announces Earnings Results
Chimerix, Inc. (NASDAQ:CMRX) announced its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.05, Bloomberg Earnings reports. The firm had revenue of $0.68 million during the quarter, compared to the consensus estimate of $1.28 million. Chimerix had a negative return on equity of 24.07% and a negative net margin of 1,221.34%.
Chimerix (CMRX) traded down 0.20% on Tuesday, hitting $4.92. The stock had a trading volume of 57,789 shares. The firm has a 50-day moving average of $5.21 and a 200 day moving average of $5.46. Chimerix has a 52 week low of $3.66 and a 52 week high of $6.64. The company’s market capitalization is $229.52 million.
A number of research analysts have issued reports on the company. Zacks Investment Research upgraded Chimerix from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Cowen and Company restated a “hold” rating and issued a $6.00 price objective on shares of Chimerix in a research note on Friday, April 28th. Finally, FBR & Co restated a “hold” rating and issued a $7.00 price objective on shares of Chimerix in a research note on Monday, May 1st. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $7.55.
ILLEGAL ACTIVITY NOTICE: “Chimerix, Inc. (NASDAQ:CMRX) Announces Earnings Results” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/08/08/chimerix-inc-nasdaqcmrx-announces-earnings-results.html.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Teza Capital Management LLC purchased a new stake in shares of Chimerix during the first quarter valued at approximately $135,000. American International Group Inc. raised its stake in shares of Chimerix by 7.1% in the first quarter. American International Group Inc. now owns 26,281 shares of the biopharmaceutical company’s stock valued at $168,000 after buying an additional 1,733 shares during the last quarter. State of Wisconsin Investment Board purchased a new stake in shares of Chimerix during the second quarter valued at approximately $185,000. Trexquant Investment LP purchased a new stake in shares of Chimerix during the first quarter valued at approximately $226,000. Finally, Metropolitan Life Insurance Co. NY purchased a new stake in shares of Chimerix during the first quarter valued at approximately $226,000. Hedge funds and other institutional investors own 65.63% of the company’s stock.
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.